537. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and
microvascular complications in type 2 diabetes. BMJ 317:703–713, 1998
538. Hansson L, Zanchett A, Carruthers SG, Bahlof B, Elmsfeldt D, Julius S, Menard J, Rahn KH, Wedel
H, Westerling S: Effects of intensive blood pressure lowering a low-dose aspirin in patients with
hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. The
HOT Study Group. Lancet 351:1755–1762, 1998
539. Ruggenenti P, Remuzzi G: Angiotensin-converting enzyme inhibitor therapy for nondiabetic progres-
sive renal diseas. Curr Opin Nephrol Hypertens 6:489–495, 1997
540. Weir MR, Dworkin L: Antihypertensive drugs, dietary salt, and renal protection: How low should
you go with which therapy? Am J Kidney Dis 32:1–22, 1998
541. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, et al: Renoprotective
effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med 345:851–860, 2001
542. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snappinn
SM, Zhang Z, Shahinfav S: The RENAAL Study Investigators. Effects of losartan on renal and cardio-
vascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869,
2001
543. Estacio ROM, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine
as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabe-
tes and hypertension. N Engl J Med 338:645–652, 1998
544. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de
Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck J: Effect of angiotensin-converting-enzyme inhibi-
tion compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:
The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611–616, 1999
545. Yusuf S, Sleigh P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Preven-
tion Evaluation Study Investigators. N Engl J Med 342:143–153, 2000
546. Jafar TH, Schmid CH, Landa M, Giatras I, Toto RDA, Remuzzi G, Maschio G, Brenner BM, et al,
for the AIPRD Study Group: Angiotensin-converting enzyme inhibitors and the progression of non-
diabetic renal disease: A meta-analysis of patient level data. Ann Intern Med 135:73–87, 2001
547. Agodoa LY, Appel L, Bakris GL, Beck GJ, Bourgoignie JJM, Briggs JP, Charleston J, Cheek D, Cleve-
land W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y,
Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz
M, Massry S, Middleton J, Miller ER 3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V,
Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD,
Wright JT Jr, Xu S: African American Study of Kidney Disease and Hypertension (AASK) Study Group.
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized
controlled trial. JAMA 285:2719–2728, 2001
548. Teschan PE, Beck GJ, Dwyer JT, Greene T, Klahr S, Levey AS, Mitch WE, Snetselaar LG, et al: Effect
of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal
disease: A reanalysis of the MDRD feasibility study. Clin Nephrol 50:273–283, 1998
549. Pedrini MT, Levey AS, Lau JY, Chalmers TC, Wang PH: The effect of dietary protein restriction on
the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:
627–632, 1996
550. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction
on the rate of decline in renal function. Am J Kidney Dis 31:954–961, 1998
551. Krolewski AS, Warram JHG, Christlieb AR: Hypercholesterolemia—A determinant of renal function
loss and deaths in IDDM patients with nephropathy. Kidney Int 45:S125-S131, 1994 (suppl 45)
552. Ma
¨
ntta
¨
ri M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline
in renal function. Hypertension. Hypertension 26:670–675, 1995
553. Gall MA, Hougaard P, Borch-Johnsen K, Parving H-H: Risk factors for development of incipient and
overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective,
observational study. BMJ 314:783–788, 1997
554. Muntner PM, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal
dysfunction: The atherosclerosis risk in communities study. Kidney Int 58:293–301, 2000
555. Scanferla F, Toffoletto PP, Roncali D, Bazzato G: Associated effect of hepatic hydroxymethylglutaryl
322 Bibliography National Kidney Foundation K/DOQI